LLY
Eli Lilly and Company
Set alert
- YTD
- +31.90%
- 1 year
- +67.86%
- Open
- 1,428.83
- Prev close
- 1,373.70
- Mkt cap
- 1.26T
- Vol
- 5.25M
- Avg vol
- 2.52M
- EPS
- 29.79
- P/E
- 47.58
- Div yield
- 0.50%
More statistics
- Low
- 1,409.00
- High
- 1,449.68
- Forward P/E
- 28.70
- Beta
- 0.00
- Short ratio
- 3.00
- Inst. own
- 85.39%
- Dividend
- 6.92
- Ex-div date
- Nov 12, 2026
- Earnings
- Feb 3, 2027
- 50-d avg
- 1,193.68
- 200-d avg
- 1,089.52
- 1y target
- 1,377.71
Key statistics
- Market cap
- 1.26T
- Enterprise value
- 0
- Trailing P/E
- 47.55
- Forward P/E
- 28.70
- PEG ratio
- 1.32
- Price / sales
- 14.59
- Price / book
- 47.77
- EPS (TTM)
- 29.79
- Beta
- 0.00
- Dividend yield
- 0.50%
- Payout ratio
- 21.69%
- Profit margin
- 31.90%
- Revenue (TTM)
- 86.46B
- Revenue growth
- 38.60%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 890.75M
- Short % of float
- 0.78%
- 50-day average
- 1,193.68
- 200-day average
- 1,089.52
Analyst view
Consensus: buy
- Target (low)
- 930.00
- Target (mean)
- 1,377.71
- Target (high)
- 1,650.00
- Strong buy6
- Buy20
- Hold3
- Sell1
- Strong sell1
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 11.12.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 10.46 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 5.71 | 7.48 | +1.77 | +31.00% |
| Aug 5, 2026 | Jun 30, 2026 | 6.40 | 8.38 | +1.98 | +30.94% |
| Apr 30, 2026 | Mar 31, 2026 | 6.97 | 8.55 | +1.58 | +22.67% |
| Feb 4, 2026 | Dec 31, 2025 | 6.91 | 7.54 | +0.63 | +9.12% |
| Oct 30, 2025 | Sep 30, 2025 | 5.69 | 7.02 | +1.33 | +23.37% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Oct 30, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 30, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 30, 2026 | Truist Securities | reit | Buy | Buy |
| Oct 30, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 30, 2026 | Argus Research | main | Buy | Buy |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- lilly.com
News
- Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism
- What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Call
- JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $1650
- Scotiabank Maintains Sector Outperform on Eli Lilly, Raises Price Target to $1605
- Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1596
- Eli Lilly 'Deserves' Stock Upside: Analyst
- Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1500
- RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1600
- Truist Securities Reiterates Buy on Eli Lilly, Raises Price Target to $1612
- LLY Q3 Earnings Call Highlights Raised Outlook and Obesity Drug Growth
Your note
Sign in to keep a note on LLY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALVAREZ RALPH | Director | Stock Award(Grant) | Oct 18, 2026 | 56,606 |
| FYRWALD J. ERIK | Director | Stock Award(Grant) | Oct 18, 2026 | 75,544 |
| HAKIM ANAT | General Counsel | Sale | Aug 6, 2026 | 0 |
| HERNANDEZ EDGARDO | Officer | Stock Gift | Sep 1, 2026 | 46,956 |
| JONSSON PATRIK | Officer | Sale | Aug 16, 2026 | 54,779 |
| LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | May 5, 2026 | 91,881,200 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lilly Endowment, Inc | 9.57% | 90,066,978 | 127.58B | Sep 29, 2026 |
| Blackrock Inc. | 7.17% | 67,540,400 | 95.67B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 5.69% | 53,528,868 | 75.83B | Jun 29, 2026 |
| PNC Financial Services Group, Inc. | 5.45% | 51,322,720 | 72.70B | Jun 29, 2026 |
| State Street Corporation | 3.85% | 36,215,754 | 51.30B | Jun 29, 2026 |
| FMR, LLC | 3.02% | 28,462,475 | 40.32B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.86% | 26,907,512 | 38.12B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.18% | 20,499,297 | 29.04B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.13% | 10,662,009 | 15.10B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.09% | 10,268,704 | 14.55B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.05% | 9,899,468 | 14.02B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Growth Index Fund | 0.94% | 8,873,900 | 12.57B | Jun 29, 2026 |